Table 3.
Quality assessment of registration information on special items (n, %)
| No. Item name | COVID19 (n = 129) | H1N1 (n = 7) | Total (n = 136) |
|---|---|---|---|
| 13. Interventions | |||
| 13.1 Intervention name | 129 (100.0%) | 7 (100.0%) | 136 (100.0%) |
| 13.2 Ingredients or detail technique | 13 (10.1%) | 1 (14.3%) | 14 (10.3%) |
| 13.3 Form | 55 (42.6%) | 4 (57.1%) | 59 (43.4%) |
| 13.4 Dosage and frequency | 20 (15.5%) | 4 (57.1%) | 24 (17.6%) |
| 13.5 Treatment duration | 6 (4.7%) | 0 (0.0%) | 6 (4.4%) |
| 13.6 Control group | 103 (79.8%) | 7 (100.0%) | 110 (80.9%) |
| Total average | 54.3 (42.1%) | 3.8 (54.8%) | 58.1 (42.7%) |
| 14. Key inclusion and exclusion criteria | |||
| 14.1 Criteria of inclusion and exclusion | 129 (100.0%) | 7 (100.0%) | 136 (100.0%) |
| 14.2 Gender | 129 (100.0%) | 7 (100.0%) | 136 (100.0%) |
| 14.3 Age | 109 (84.5%) | 7 (100.0%) | 116 (85.3%) |
| 14.4 Diagnosis criteria—Western medicine | 45 (34.9%) | 2 (28.6%) | 47 (34.6%) |
| 14.5 With healthy human volunteer | 1 (0.8%) | 0 (0.0%) | 1 (0.7%) |
| Total average | 82.6 (64.0%) | 4.6 (65.7%) | 87.2 (64.1%) |
| 15. Study type | |||
| 15.1 Type of study | 129 (100.0%) | 7 (100.0%) | 136 (100.0%) |
| 15.2 Method of allocation (randomized/non-randomized) | 107 (82.9%) | 5 (71.4%) | 112 (82.4%) |
| 15.3 Masking (is masking used and, if so, who is masked) | 46 (35.7%) | 2 (28.6%) | 48 (35.3%) |
| 15.4 Assignment (single arm, parallel, crossover, or factorial) | 107 (82.9%) | 7 (100.0%) | 114 (83.8%) |
| 15.5 Allocation concealment mechanism | 6 (4.7%) | 0 (0.0%) | 6 (4.4%) |
| 15.6 Phase (if applicable) | 79 (61.2%) | 5 (71.4%) | 84 (61.8%) |
| Total average | 79.0 (61.2%) | 4.3 (61.9%) | 83.3 (61.3%) |
| 19. Primary outcome(s) | |||
| 19.1 Name | 128 (99.2%) | 7 (100.0%) | 135 (99.3%) |
| 19.2 Measurement of primary outcome(s) | 2 (1.6%) | 0 (0.0%) | 2 (1.5%) |
| 19.3 Time point of measurements | 17 (13.2%) | 1 (14.3%) | 18 (13.2%) |
| Total average | 49.0 (38.0%) | 2.7 (38.1%) | 51.7 (38.0%) |
| 20. Key secondary outcome(s) | |||
| 20.1 Name | 89 (69.0%) | 7 (85.7%) | 96 (70.6%) |
| 20.2 Measurements of key secondary outcomes | 2 (1.6%) | 0 (0.0%) | 2 (1.5%) |
| 20.3 Time point of measurements | 15 (11.6%) | 1 (14.3%) | 16 (11.8%) |
| Total average | 35.3 (27.4%) | 2.7 (38.1%) | 38.0 (27.9%) |
| 21. Ethics review | |||
| 21.1 Ethics review status | 125 (96.9%) | 6 (83.3%) | 131 (96.3%) |
| 21.2 Date of approval | 98 (76.0%) | 4 (69.0%) | 102 (75.0%) |
| 21.3 Name of ethics committee(s) | 105 (81.4%) | 4 (78.6%) | 109 (80.1%) |
| 21.4 Contact details of ethics committee(s) | 104 (80.6%) | 0 (40.5%) | 104 (76.4%) |
| Total average | 108.0 (83.7%) | 4.0 (57.1%) | 112.0 (82.4%) |
| 23. Summary results | |||
| 23.1 Date of posting of result summaries | 0 (0%) | 0 (0%) | 0 (0%) |
| 23.2 Date of the first journal publication of results | 0 (0%) | 0 (0%) | 0 (0%) |
| 23.3 URL hyperlink(s) related to results or a full reference list of publications | 0 (0%) | 0 (0%) | 0 (0%) |
| 23.4 Baseline characteristics | 0 (0%) | 0 (0%) | 0 (0%) |
| 23.5 Participant flow, adverse events | 0 (0%) | 0 (0%) | 0 (0%) |
| 23.6 Adverse events | 0 (0%) | 0 (0%) | 0 (0%) |
| 23.7 Outcome measures | 0 (0%) | 0 (0%) | 0 (0%) |
| 23.8 URL link to protocol file(s) with version and date | 0 (0%) | 0 (0%) | 0 (0%) |
| Changes to protocol | 0 (0%) | 0 (0%) | 0 (0%) |
| Total average | 0 (0%) | 0 (0%) | 0 (0%) |
| Total special items average report percentage (%) | 45.6% | 45.1% | 45.6% |
COVID-19 severe acute respiratory syndrome coronavirus 2, H1N1 H1N1 influenza